Well Lead Medical Co., Ltd. (SHA:603309)
11.49
-0.39 (-3.28%)
Jul 31, 2026, 3:00 PM CST
Well Lead Medical Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,655 | 1,631 | 1,509 | 1,388 | 1,363 | 1,119 |
Revenue Growth | 4.85% | 8.07% | 8.76% | 1.79% | 21.88% | -1.07% |
Gross Profit Gross Profit Growth | 716.98 | 720.15 | 662.88 | 625.1 | 578.37 | 471.76 |
Operating Income Operating Income Growth | 270.27 | 285.86 | 254.9 | 234.42 | 197.13 | 149.16 |
Net Income Net Income Growth | 57.25 | 76.33 | 219.39 | 192.49 | 166.57 | 106.09 |
Earnings Per Share EPS Growth | 0.20 | 0.26 | 0.75 | 0.66 | 0.57 | 0.41 |
EPS Growth | -75.47% | -65.33% | 13.64% | 15.79% | 39.02% | -30.51% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
China China Growth | 685.8 |
Overseas Overseas Growth | 919.31 |
Total Total Growth | 1,605 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 434.6 | 519.05 | 480.26 | 446.95 | 703.96 | 634.77 |
Total Debt Total Debt Growth | 619.92 | 622.38 | 508.2 | 397.08 | 260 | 244.62 |
Net Cash (Debt) Net Cash Growth | -185.32 | -103.33 | -27.94 | 49.87 | 443.96 | 390.15 |
Net Cash Growth | - | - | - | -88.77% | 13.79% | 1309.49% |
Net Cash Per Share Net Cash Per Share Growth | -0.64 | -0.35 | -0.10 | 0.17 | 1.52 | 1.51 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 456.63 | 330.26 | 306.26 | 222.51 | 391.13 | 187.28 |
Capital Expenditures CapEx Growth | -210.2 | -206.15 | -315.73 | -357.89 | -181.38 | -109.28 |
Free Cash Flow Free Cash Flow Growth | 246.44 | 124.11 | -9.47 | -135.38 | 209.75 | 78 |
Free Cash Flow Growth | - | - | - | - | 168.90% | -42.63% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 43.33% | 44.15% | 43.92% | 45.04% | 42.42% | 42.18% |
Operating Margin | 16.33% | 17.52% | 16.89% | 16.89% | 14.46% | 13.33% |
Pretax Margin | 6.57% | 7.99% | 17.43% | 17.10% | 15.08% | 12.54% |
Profit Margin | 3.46% | 4.68% | 14.54% | 13.87% | 12.22% | 9.49% |
FCF Margin | 14.89% | 7.61% | -0.63% | -9.75% | 15.38% | 6.97% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.600 | 0.500 | 0.500 | 0.500 | 0.340 | 0.135 |
Dividend Per Share Growth | 0% | 0% | 0% | 47.06% | 151.85% | -32.50% |
Dividend Yield | 5.22% | 3.82% | 4.52% | 3.96% | 1.95% | 0.99% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 58.53 | 51.97 | 15.99 | 21.67 | 35.18 | 39.36 |
Forward PE | 10.64 | 13.73 | 13.24 | 19.76 | 80.30 | 80.30 |
P/FCF Ratio | 13.61 | 31.96 | - | - | 27.94 | 53.53 |
PS Ratio | 2.03 | 2.43 | 2.33 | 3.01 | 4.30 | 3.73 |